LLY · 8-K · 20260430PR000043
Key Products Concentration
ELI LILLY & Co · 2026-04-30 · Importance 89 · Surprise 82 · No source text
Key Products revenue grew to $13.4 billion in Q1 2026, with Mounjaro and Zepbound identified as leading contributors. The company defines Key Products as Ebglyss, Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound (Verzenio excluded effective Q1 2026). Key Products revenue in the Immunology, Oncology, and Neuroscience therapeutic areas grew 160% in Q1 2026 versus Q1 2025, indicating rapid concentration in those portfolios. This concentration reflects outsized growth in newly launched and recently expanded therapies during Q1 2026.
Key facts
- Key Products revenue grew to $13.4 billion in Q1 2026 source
- Key Products revenue in Immunology, Oncology, and Neuroscience grew 160% in Q1 2026 compared to Q1 2025 source
- The Company currently defines Key Products as Ebglyss, Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound and effective Q1 2026 Verzenio is excluded from Key Products source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Key Products revenue grew to $13.4 billion in Q1 2026 |
| revenue | positive | realized | — | Key Products revenue in Immunology, Oncology, and Neuroscience grew 160% in Q1 2026 compared to Q1 2025 |